Programmed death
Upregulation of programmed death 1 on T cells and programmed death ligand 1 on monocytes in septic shock patients
... Figure 2 PD-1 and PD-L1 were upregulated on T cells and monocytes in septic shock patients. Blood samples were obtained from 19 septic shock patients and 22 healthy controls and were stained for programmed ...
9
<p>Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer</p>
... of programmed death receptor-1/programmed death ligand 1 (PD-1/PD-L1) can stimulate surrounding T cells and thus have antitumor effects in the ...
17
The Expression of Programmed Death Ligand-1 within Stages of Oral Squamous Cell Carcinoma: Immunohistochemical Analysis
... (n=37). Programmed Death Ligand-1 positivity was observed in ...of Programmed Death Ligand-1 with stage II and IV ...of Programmed Death Ligand-1 with other variables such as ...
10
Original Article Programmed death-1 and PD-1 ligand-1 expression in early onset gastric carcinoma and correlation with clinicopathological characteristics
... Abstract: Purpose: Early onset gastric carcinoma (EOGC) is thought to be developed by a distinct molecular genetic profile of gastric carcinoma occurring at an older age. The aim of this study was to compare ...
10
<p>Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer</p>
... the programmed cell death 1 protein (PD-1) and the programmed death-ligand 1 protein (PD-L1) have been pro- ven to be effective in a number of cancer ...
16
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
... 1: Programmed death 1; PD-L1: Programmed death ligand 1; TMB: Tumor mutational burden; MMRd: Mismatch repair deficient; MSI-H: Microsatellite instabibility high; MMRp: Mismatch repair ...
8
Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer
... PD-1: Programmed cell death 1; PD-L1: Programmed death-ligand 1; GC: Gastric cancer; GEO: Gene Expression Omnibus; GSEA: Gene set enrichment analysis; OS: Overall survival; TME: Tumor ...
13
A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients
... PD-L1: Programmed death-ligand 1; PD-1: Programmed death-1; HR: Hazard ratio; CI: Confidence interval; OS: Overall survival; PFS: Progression-free survival; LN: Lymph node; AJCC: American ...
11
Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report
... Background: Immune checkpoint blockade targeting programmed cell death ligand-1 (PD-L1)/ programmed death-1 (PD-1) signaling was approved recently for locally advanced and metastatic u[r] ...
10
Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
... anti-programmed death (PD-1) antibody, has shown favorable antitumor efficacy in NSCLC patients [1, ...of programmed death ligand 1 (PD-L1) expression (tumor proportion score [TPS] ≥ 50%) ...
5
<p>BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes</p>
... block programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4), among others, to reverse the immune escape abilities of tumor ...
10
Original Article PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes
... CD86, programmed death (PD-1), programmed death ligand 1 (PD-L1), paired immunoglobulin-like receptor B (PIR-B) or T-cell proliferation in serum, spleen homogenate, DC culture or DC/T-cell ...
10
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
... anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibody has a good effect in the treatment of non-small cell lung cancer (NSCLC), but not all PD-1/PD-L1 positive ...
6
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
... Additional file 1: Figure S1. Study design and pharmacokinetic/ pharmacodynamic assessment. (a) phase I study design. (b) Overview of pharmacokinetic and pharmacodynamic profile assessment. Figure S2. MEDI0680 binding ...
15
Programmed cell death in mouse primordial germ cells
... From our early studies it was clear that PGCs require multiple factors to avoid activation of intrinsic apoptotic pathways. The ad- vantages of having PGC survival depending on signals produced by the surrounding somatic ...
10
Immunotherapy for Merkel cell carcinoma: a turning point in patient care
... get programmed cell death protein 1 (PD-1), another im- mune checkpoint receptor, or one of its associated ligands (PD-L1), and are now FDA-approved for a variety of can- cers ...
6
Regulation of caspase activation during programmed cell death
... cell death, ced-9 (Hengartner et a l, ...the death of cells that normally die during development and mutations that inactivated ced-9 caused cells to die that normally ...
191
Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis
... Although much of the focus and excitement of anti- PD-1 antibody therapy has been in the field of oncology, in which it has been demonstrated to be highly effective in inducing remissions in patients with a variety of ...
15
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
... T cell infiltration in certain human tumors is associ- ated with an improved clinical outcome [9, 10]. The accumulating evidence suggests that tumors can be clas- sified into two groups: Immunologically-ignorant tumors ...
25
Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy
... cell death protein 1 ...ligands programmed cell death protein ligand 1 (PD-L1) and programmed cell death protein ligand 2 (PD-L2), which are expressed in peripheral tissues and ...
7